During a 24-months observation period, 20.5% (32 out of 156 mice) of Arh1-deficient and 11% (19 out of 169 mice) of Arh1-heterozygous mice showed increased frequency and extent of tumors in multiple organs, e.g., adenocarcinoma in lung, uterus, and mammary gland; hepatocellular carcinoma; hepatic and gastrointestinal lymphoma; hemangiosarcoma [40]. This evidence concerns the gene ADPRH and hepatocellular carcinoma.